Go Pro
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel
NASDAQ:ONCO

Onconetix Q2 2025 Earnings Report

Onconetix logo
$1.03 +0.12 (+13.07%)
Closing price 04:00 PM Eastern
Extended Trading
$1.14 +0.11 (+10.19%)
As of 05:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Onconetix EPS Results

Actual EPS
-$202.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Onconetix Revenue Results

Actual Revenue
$0.11 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Onconetix Announcement Details

Quarter
Q2 2025
Date
8/14/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Onconetix's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Onconetix Earnings Headlines

SRX Global Inc: SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)
September 25 at 9:10 AM  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69675548-srx-global-inc-srx-global-provides-shareholders-with-update-on-liquidation-of-two-portfolio-investments-and-adds-an-investment-in-onconetix-nasdaq-399.htm
SRX Global Makes Investment in Onconetix
September 24 at 2:35 PM  |  finance.yahoo.comhttps://finance.yahoo.com/technology/ai/articles/srx-global-makes-investment-onconetix-171429009.html
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
September 25 at 1:00 AM  |  Weiss Ratings (Ad)
SRX Global Inc. acquired an unknown minority stake in Onconetix, Inc..
September 24 at 2:35 PM  |  marketscreener.comM
Onconetix, Inc.: CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
September 15, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69580711-onconetix-inc-corrected-onconetix-provides-strategic-bridge-financing-to-realbotix-llc-in-support-of-pending-acquisition-399.htm
Onconetix Provides Up To $5 Mln Bridge Financing To Realbotix
September 15, 2026  |  rttnews.comhttps://www.rttnews.com/3691164/onconetix-provides-up-to-5-mln-bridge-financing-to-realbotix.aspx
See More Onconetix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Onconetix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Onconetix and other key companies, straight to your email.

About Onconetix

Onconetix (NASDAQ:ONCO) is a biotechnology company focused on developing and commercializing products for men’s health and oncology. The company’s activities center on therapies and diagnostic technologies intended to address conditions affecting the prostate and related areas of healthcare.

Onconetix’s lead commercial product is ENTADFI, an oral combination of tadalafil and finasteride approved by the U.S. Food and Drug Administration for the treatment of the signs and symptoms of benign prostatic hyperplasia, or BPH, in men with an enlarged prostate. Tadalafil may help improve urinary symptoms, while finasteride is intended to reduce prostate size over time.

The company was formerly known as Blue Water Vaccines and adopted the Onconetix name as its business strategy shifted toward men’s health and oncology. Its operations and commercial focus are primarily directed toward the United States. Information about additional products, geographic expansion and current leadership may change as the company develops its pipeline and commercialization strategy.

View Onconetix Profile
Earnings Tools